Madsen, P
Fosgonimeton Phase 1 Trials M3 Biotechnology (later Athira Pharma) completes Phase 1 safety trials of fosgonimeton, a prodrug of Dihexa
We modeled a budget neutrality adjustment for the final cancer hospital payment adjustment because the final payment-to-cost ratio target for the cancer hospital payment adjustment in CY 2026 is 0.87, which is the same PCR target adopted in the CY 2025 OPPS/ASC final rule with comment period (89 FR 93979)
Capsules require consistency, clean manufacturing standards, and responsible handling
beyond this, any haze or discoloration warrants immediate disposal
Another study with a brain-specific functional interaction network constructed a genome-wide probabilistic graph that was composed of genes, pathways, and their functions, integrating numerous genomic experiments (Krishnan et al., 2016)